التفاصيل البيبلوغرافية
| العنوان: |
A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T‐cell therapy |
| المؤلفون: |
Cao, Xing‐yu1,2 (AUTHOR) caoxingyu2020@sina.com, Zhang, Jian‐ping1,2 (AUTHOR), Lu, Yue1,2 (AUTHOR), Zhao, Yan‐li1,2 (AUTHOR), Liu, De‐yan1,2 (AUTHOR), Xiong, Min1,2 (AUTHOR), Sun, Rui‐juan1,2 (AUTHOR), Wei, Zhi‐jie1,2 (AUTHOR), Zhou, Jia‐rui1,2 (AUTHOR), Zhang, Xian1,2 (AUTHOR), Yang, Jun‐fang1,2 (AUTHOR), Li, Jingjing1,3 (AUTHOR), Lu, Peihua1,2,3 (AUTHOR) peihua_lu@126.com |
| المصدر: |
British Journal of Haematology. Jun2024, Vol. 204 Issue 6, p2351-2364. 14p. |
| مصطلحات موضوعية: |
*STEM cell transplantation, *HEMATOPOIETIC stem cell transplantation, *LYMPHOBLASTIC leukemia, *CHIMERIC antigen receptors, *ACUTE leukemia, *T cells |
| مستخلص: |
Summary: CD7‐targeted chimeric antigen receptor T‐cell (CAR‐T) therapy has shown promising initial complete remission (CR) rates in patients with refractory or relapsed (r/r) T‐cell acute lymphoblastic leukaemia and lymphoblastic lymphoma (T‐ALL/LBL). To enhance the remission duration, consolidation with allogeneic haematopoietic stem cell transplantation (allo‐HSCT) is considered. Our study delved into the outcomes of 34 patients with r/r T‐ALL/LBL who underwent allo‐HSCT after achieving CR with autologous CD7 CAR‐T therapy. These were compared with 124 consecutive T‐ALL/LBL patients who received allo‐HSCT in CR following chemotherapy. The study revealed that both the CAR‐T and chemotherapy cohorts exhibited comparable 2‐year overall survival (OS) (61.9% [95% CI, 44.1–78.1] vs. 67.6% [95% CI, 57.5–76.9], p = 0.210), leukaemia‐free survival (LFS) (62.3% [95% CI, 44.6–78.4] vs. 62.0% [95% CI, 51.8–71.7], p = 0.548), non‐relapse mortality (NRM) rates (32.0% [95% CI, 19.0–54.0] vs. 25.3% [95% CI, 17.9–35.8], p = 0.288) and relapse incidence rates (8.8% [95% CI, 3.0–26.0] vs. 15.8% [95% CI, 9.8–25.2], p = 0.557). Patients aged ≤14 in the CD7 CAR‐T group achieved high 2‐year OS and LFS rates of 87.5%. Our study indicates that CD7 CAR‐T therapy followed by allo‐HSCT is not only effective and safe for r/r T‐ALL/LBL patients but also on par with the outcomes of those achieving CR through chemotherapy, without increasing NRM. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
